血管内皮抑素（ES）是一种内源性的血管生成抑制因子，具有广谱的抗肿瘤效应。但临床为达到较好疗效需大剂量给药，且因半衰期短需持续用药，存在疗效难以保证和治疗成本昂贵的问题，新的给药方法在不断探索中。表达tie2单核细胞（TEM)为新发现的一种肿瘤组织特异性细胞，是一种靶向肿瘤的细胞载体。本项目在小鼠模型中以TEM细胞为载体靶向递送分泌型ES治疗肿瘤，研究治疗的安全性和效果及其机制。首先制备连接tie2启动子的ES基因的假病毒VSV-G（Tie2-ES），然后感染体外扩增后的小鼠造血干细胞，再将感染干细胞（获得靶向TEM（Tie2-ES））植入致死剂量照射小鼠并接入不同肿瘤以检测靶向治疗的效果并研究其抗肿瘤机制。本项目将在小鼠肿瘤模型中阐明TEM靶向送ES的效果和安全性及其机制，为靶向治疗应用于临床奠定基础。

Endostatin（ES）, a endogenous angiogenesis inhibitor, suppresses vascular depended tumoror growth in various cancers. But the use of ES has been limited by ineffective dosing and high cost. New methods to deliver ES is in development. tie2-expressing monocytes (TEM) have tumor-homing specificity, can be used as tumor targeted vehicles. This study intends to develope a method to deliver secretable ES with TEM. Fistly, prepare for the pesudovirus VSV-G（Tie2-ES）expressing the mouse ES by a mouse tie2 promoter, then, transfected the hematopoietic stem/progenitor cell of mice and generate TEM-ES mice by transplanted the infected stem cells into lethally irradiated mice. Thirdly, the TEM-ES mice models were used to study whether turmor targeted ES can surppres various tumor growth as well as the antitumor mechanism. The result of this study will elucidate the safety and the efficiency of the mew method to deliver ES with TEM in mouse models which can give a base for threapeutic potential.